NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT INFORMATION AT THE END OF THE ANNOUNCEMENT
Oslo, 14 May 2018: Reference is made to the stock exchange announcement by Vistin Pharma ASA ("Vistin Pharma" or the "Company") published on 9 May 2018 regarding the subsequent repair issue (the "Subsequent Repair Issue") and listing of up to 31,250,001 shares, of which 26,785,715 shares (the "Private Placement Shares") have been issued in connection with the private placement and up to 4,464,286 new shares (the "Offer Shares").
The subscription period in the Subsequent Repair Issue commences today on 14 May 2018 and will expire on 25 May 2018 at 16:30 hours CEST. Shareholders in the Company as of 22 March 2018, as registered in the VPS on 26 March 2018, who were not allocated shares in the Private Placement and who are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action, will be eligible to participate in the Subsequent Repair Issue and will be allocated subscription rights.Subscription Rights that are not used to subscribe for Offer Shares before 16:30 hours (CEST) on 25 May 2018 will have no value and will lapse without compensation to the holder.
DNB Markets, a part of DNB Bank ASA, is acting as Manager for the private placement and the Subsequent Repair Issue.
For more information, please refer to the prospectus of the Company dated 9 May 2018. The Prospectus including the subscription form is available at the following websites: http://www.vistin.com/ and www.dnb.no/emisjoner .
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
Gunnar Manum
CFO +47 951 79 190
